Paul Peter Tak, M.D., Ph.D., FMedSci
2023
In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci earned a total compensation of $1.5M as Chief Executive Officer at Candel Therapeutics, a 20% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $134,000 |
---|---|
Option Awards | $189,558 |
Salary | $670,000 |
Stock Awards | $176,506 |
Other | $314,695 |
Total | $1,484,759 |
FMedSci received $670K in salary, accounting for 45% of the total pay in 2023.
FMedSci also received $134K in non-equity incentive plan, $189.6K in option awards, $176.5K in stock awards and $314.7K in other compensation.
Rankings
In 2023, Paul Peter Tak, M.D., Ph.D., FMedSci's compensation ranked 792nd out of 2,918 executives tracked by ExecPay. In other words, FMedSci earned more than 72.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 792 | 73rd |
Manufacturing | 469 | 71st |
Chemicals And Allied Products | 320 | 65th |
Drugs | 312 | 64th |
Biological Products, Except Diagnostic Substances | 99 | 53rd |
FMedSci's colleagues
We found two more compensation records of executives who worked with Paul Peter Tak, M.D., Ph.D., FMedSci at Candel Therapeutics in 2023.